Navigation Links
Champions' CFO Resigns
Date:1/14/2011

BALTIMORE, Jan. 14, 2011 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced today the resignation of Mark Schonau, Champions' Chief Financial Officer. Mr. Schonau indicated that he has no disagreements with management and has resigned to pursue other opportunities. Champions is seeking chief financial officer candidates and intends to complete the search in the near future.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced translational platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Technology Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Champions Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.

www.championsbiotechnology.com

Contact: Joel Ackerman, CEO, 410 369 0365


'/>"/>
SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Champions Biotechnology Awarded $1.46 million in Grants
2. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
3. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
4. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
5. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
6. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. John A. MacPhee Resigns From Strativa Pharmaceuticals
10. Paul D. Duke Resigns From Mesas Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)...  AOTI Inc. announced today that its fully owned ... a New York City Office in Yonkers, New York ... Wound Oxygen (TWO 2 ) homecare therapy. This new East Coast ... Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable Medical Equipment ... Advanced Oxygen Therapy ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
(Date:8/7/2017)... FLINT, Mich. , Aug. 7, 2017 Diplomat ... appointment of Joel Saban as president, effective Aug. ... Paul Urick has decided to pursue other interests and ... period. "During his tenure, Paul has served us in multiple ... Burman,s Specialty Pharmacy in Jun. 2015 and has provided decisive, ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... ... received a three-year grant totaling $975,000, renewing its funding from the Health Resources ... Services. , This funding marks, the fourth time the HRSA administration has renewed ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of Infection Control ... cycle, both between patient procedures and before storage, is a requisite practice crucial ... to the prevention of disease transmission and nosocomial infection as cleaning and HLD.” ...
(Date:8/16/2017)... ... 16, 2017 , ... Connexion Point, a technology-enabled healthcare services company delivering outcome ... year. With 197% revenue growth over the past three years, Connexion Point ... , Previous honors include ranking 86th on the Inc. 500 in 2014, ...
(Date:8/16/2017)... ... August 16, 2017 , ... First Choice Emergency Room ... Dr. Douglas J. Harrison, as the new Medical Director of its Sienna Plantation facility. ... Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) Caraway, Area Medical ...
(Date:8/16/2017)... ... August 16, 2017 , ... “God Will Break Every Chain”: an inspirational story for ... is the creation of published author, Evangelist Joann Shivers, a writer and a woman of ... on her life at an early age. She was born and raised in Vero ...
Breaking Medicine News(10 mins):